Greater Occipital Nerve Block With Bupivacaine for Acute Migraine



Status:Completed
Conditions:Migraine Headaches
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:9/2/2018
Start Date:July 1, 2015
End Date:January 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine

This is a randomized, sham-controlled study of greater occipital nerve block (GONB) using
bupivacaine 0.5% for emergency department patients with acute migraine. Patients are only
enrolled if they fail first line therapy with metoclopramide.

The investigators are testing the following hypothesis:

In a population of patients who present to an ED with acute migraine and have been treated
with parenteral metoclopramide unsuccessfully, bilateral greater occipital nerve blocks with
bupivicaine will provide greater rates of short-term and sustained headache freedom than
bupivacaine injected intradermally.

Inclusion Criteria:

- ED patient with acute migraine or probable migraine

- Fail first line therapy with metoclopramide

Exclusion Criteria:

- Can't obtain consent

- Concern for secondary headache

- Skull defect

- Propensity for bleeding

- Overlying infection

- Pregnancy

- Allergy, intolerance study medication
We found this trial at
1
site
Montefiore Medical Center
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Phone: 718-920-6626
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials